Evidence map›Paper›PMID 40887624›Full record

ArticleHuman genomics2025

Genomic and transcriptomic data reveal molecular differences between homologous recombination deficiency subgroups in Chinese ovarian cancer patients.

Hongxia Wang, Wenhong Zhao, Wenhao Zhou, Na Wang, Yijie Li, Kaiyun Qin, Jingde Jia, Jiaqian Wang, Congcong Song, Yu Yu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hongxia Wang *Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Wenhong Zhao *Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Wenhao Zhou *Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Na WangDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Yijie LiDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Kaiyun QinDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Jingde JiaDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Jiaqian WangShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Congcong SongShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Yu YuDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Fenghua ZhangDepartment of General Surgery, Hebei General Hospital, Hebei Shijiazhuang, 050051, China.
Xu CuiDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Lanlan ZhaoDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Haitao LuoShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China. luoht1985@gmail.com.
Zhengmao ZhangDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. zhangzhengmao@hbmu.edu.

Funding

Hebei Natural Science Foundation H2020206223S&T Program of Hebei 226Z7719G
6 · The paper itself

Abstract

backgroundOvarian cancer (OV) has the highest mortality rate among gynecological cancers and shows varied responses to chemotherapy combined with PARP inhibitors based on homologous recombination deficiency (HRD) subtypes.

methodsThis study enrolled 143 Chinese OV patients to determine the HRD score grouping threshold using genomic features, dividing patients into HRD-high and HRD-low groups. Multi-omics sequencing was conducted on 70 patients receiving adjuvant chemotherapy with PARP inhibitors.

resultsIn this study, TP53 mutations enriched in the HRD-high group, while ARID1A, PIK3CA, and PTEN mutations were more common in the HRD-low group. HRD-high patients exhibited stronger immune activation, including elevated STAT1 expression, HLA signatures, and increased M1 macrophage infiltration, correlating with better prognosis. Additionally, peripheral blood analysis revealed higher bMSI and maxVAF levels in HRD-low patients compared to HRD-high patients, suggesting ctDNA as a potential tool for dynamic monitoring post-treatment.

conclusionsThis study identified distinct molecular and immune profiles between HRD subgroups in Chinese ovarian cancer patients. Patients with HRD-high and STAT1 expression ≥ 74 suggests PARPi benefit.

Indexed as

Homologous RecombinationOvarian NeoplasmsTranscriptomeAdultAgedChinaClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsEast Asian PeopleFemaleGene Expression Regulation, NeoplasticGenomicsHumansMiddle AgedMutationPoly(ADP-ribose) Polymerase InhibitorsARID1A protein, humanClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsPIK3CA protein, humanPoly(ADP-ribose) Polymerase InhibitorsPTEN PhosphohydrolasePTEN protein, humanSTAT1 protein, humanSTAT1 Transcription FactorTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53CtDNAHomologous recombination deficiencyImmune responsesOvarian cancerTumor microenvironment

Identifiers

PMID40887624
PMCPMC12398958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.